A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis
Open Access
- 1 September 2017
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 262, 47-57
Abstract
No abstract availableKeywords
Funding Information
- European Framework Program 7 (FP7-Health 309820)
- National Institute of Health Grants (R01 HL118440, R01HL125703)
- Netherlands Organisation for Scientific Research (R01 EB009638, P30 CA008748)
- “De Drie Lichten”
This publication has 70 references indexed in Scilit:
- SMART drug delivery systems: Back to the future vs. clinical realityInternational Journal of Pharmaceutics, 2013
- Myocardial infarction accelerates atherosclerosisNature, 2012
- Therapeutic siRNA silencing in inflammatory monocytes in miceNature Biotechnology, 2011
- Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels–Alder Click ChemistryBioconjugate Chemistry, 2011
- Targeted drug delivery to tumors: Myths, reality and possibilityJournal of Controlled Release, 2011
- Lipoprotein-Inspired Nanoparticles for Cancer TheranosticsAccounts of Chemical Research, 2011
- Macrophages in the Pathogenesis of AtherosclerosisCell, 2011
- Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental AtherosclerosisMolecular Pharmaceutics, 2010
- Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered ReleasePharmaceutical Research, 2010
- Regulation of the mevalonate pathwayNature, 1990